Researchers have confirmed that in the earliest stages of Alzheimer's, levels of specific proteins in the blood and spinal fluid can be used to track the progression of AD, long before symptoms appear.
The hope is that, one day, screening for such biomarkers could take their place beside such routine tests as colonoscopies and mammograms as another common tool of preventive medicine.